The Art of Drug Synthesis / Edition 1

Hardcover (Print)
Buy New
Buy New from BN.com
$106.76
Used and New from Other Sellers
Used and New from Other Sellers
from $104.55
Usually ships in 1-2 business days
(Save 20%)
Other sellers (Hardcover)
  • All (10) from $104.55   
  • New (9) from $104.55   
  • Used (1) from $108.87   

Overview

The Art of Drug Synthesis illustrates how chemistry, biology, pharmacokinetics, and a host of other disciplines come together to produce successful medicines. The authors have compiled a collection of 21 representative categories of drugs, from which they have selected as examples many of the best-selling drugs on the market today. An introduction to each drug is provided, as well as background to the biology, pharmacology, pharmacokinetics, and drug metabolism, followed by a detailed account of the drug synthesis.

  • Edited by prominent scientists working in drug discovery for Pfizer
  • Meets the needs of a growing community of researchers in pharmaceutical R&D
  • Provides a useful guide for practicing pharmaceutical scientists as well as a text for medicinal chemistry students
  • An excellent follow-up to the very successful first book by these editors, Contemporary Drug Synthesis, but with all new therapeutic categories and drugs discussed.
Read More Show Less

Editorial Reviews

From the Publisher
“This is a most topical and useful short primer on estab1ished drugs and their synthesis.” (American Journal of Therapeutics, June 2009)

"The book is very felicitous and closes a gap in the literature by covering the subject of drug development in this particular way." (Angewandte Chemie, June 23, 2008)

"This book is a very entertaining read." (ChemMedChem, 2008, 3)

"The editors and contriubting authros have certainly provided a most useful book for the medicinal and organic chemistry community." (Journal of Medicinal Chemistry, March 2008)

"Where I see the book being very useful is as a starting point for student seminars or discussion groups... Also, it is highly illuminating just to dip into for a browse and to marvel at some of the excellent chemistry that goes on in the pharmaceutical industry." (Chemistry World, January 2008)

Read More Show Less

Product Details

  • ISBN-13: 9780471752158
  • Publisher: Wiley
  • Publication date: 7/9/2007
  • Series: Wiley Series on Drug Synthesis Series
  • Edition description: New Edition
  • Edition number: 1
  • Pages: 296
  • Product dimensions: 7.22 (w) x 10.20 (h) x 0.87 (d)

Meet the Author

Douglas S. Johnson, PHD, is a Research Chemist at Pfizer Global Research and Development.

Jie Jack Li, PHD, is a Research Chemist at Pfizer Global Research and Development.

Read More Show Less

Table of Contents

Foreword.

Preface.

Contributors.

1 THE ROLE OF MEDICINAL CHEMISTRY IN DRUG DISCOVERY (John A. Lowe, III).

1.1 Introduction.

1.2 Hurdles in the Drug Discovery Process.

1.3 The Tools of Medicinal Chemistry.

1.3.1 In Silico Modeling.

1.3.2 Structure-Based Drug Design (SBDD).

1.4 The Role of Synthetic Chemistry in Drug Discovery.

References.

2 PROCESS RESEARCH: HOW MUCH? HOW SOON? (Neal G. Anderson).

2.1 Introduction.

2.2 Considerations for Successful Scale-up to Tox Batches and Phase I Material.

2.3 Considerations for Phase 2 Material and Beyond.

2.3.1 Reagent Selection.

2.3.2 Solvent Selection.

2.3.3 Unit Operations.

2.3.4 Developing Simple, Effective, Efficient Work-ups and Isolations.

2.3.5 The Importance of Physical States.

2.3.6 Route Design and Process Optimization to Minimize COG.

2.4 Summary.

References.

I CANCER AND INFECTIOUS DISEASES.

3 AROMATASE INHIBITORS FOR BREAST CANCER: EXEMESTANE (AROMASIN), ANASTROZOLE (ARIMIDEX), AND LETROZOLE (FEMARA) (Jie Jack Li).

3.1 Introduction.

3.2 Synthesis of Exemestane.

3.3 Synthesis of Anastrozole.

3.4 Synthesis of Letrozole.

References.

4 QUINOLONE ANTIBIOTICS: LEVOFLOXACIN (LEVAQUIN), MOXIFLOXACIN (AVELOX), GEMIFLOXACIN (FACTIVE), AND GARENOXACIN (T-3811) (Chris Limberakis).

4.1 Introduction.

4.1.1 Mechanism of Action.

4.1.2 Modes of Resistance.

4.1.3 Structure–Activity Relationship (SAR) and Structure–Toxicity Relationship (STR).

4.1.4 Pharmacokinetics.

4.1.5 Synthetic Approaches.

4.2 Levofloxacin.

4.3 Moxifloxacin.

4.4 Gemifloxacin.

4.5 Garenoxacin (T-3811): A Promising Clinical Candidate.

References.

5 TRIAZOLE ANTIFUNGALS: ITRACONAZOLE (SPORANOX), FLUCONAZOLE (DIFLUCAN), VORICONAZOLE (VFEND), AND FOSFLUCONAZOLE (PRODIF) (Andrew S. Bell).

5.1 Introduction.

5.2 Synthesis of Itraconazole.

5.3 Synthesis of Fluconazole.

5.4 Synthesis of Voriconazole.

5.5 Synthesis of Fosfluconazole.

References.

6 NON-NUCLEOSIDE HIV REVERSE TRANSCRIPTASE INHIBITORS (Arthur Harms).

6.1 Introduction.

6.2 Synthesis of Nevirapine.

6.3 Synthesis of Efavirenz.

6.4 Synthesis of Delavirdine Mesylate.

References.

7 NEURAMINIDASE INHIBITORS FOR INFLUENZA: OSELTAMIVIR PHOSPHATE (TAMIFLU) AND ZANAMIVIR (RELENZA) (Douglas S. Johnson and Jie Jack Li).

7.1 Introduction.

7.1.1 Relenza.

7.1.2 Tamiflu.

7.2 Synthesis of Oseltamivir Phosphate (Tamiflu).

7.3 Synthesis of Zanamivir (Relenza).

References.

II CARDIOVASCULAR AND METABOLIC DISEASES.

8 PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) AGONISTS FOR TYPE 2 DIABETES (Jin Li).

8.1 Introduction.

8.1.1 Insulin.

8.1.2 Sulfonylurea Drugs.

8.1.3 Meglitinides.

8.1.4 Biguanides.

8.1.5 Alpha-Glucosidase Inhibitors.

8.1.6 Thiazolidinediones.

8.2 Synthesis of Rosiglitazone.

8.3 Synthesis of Pioglitazone.

8.4 Synthesis of Muraglitazar.

References.

9 ANGIOTENSIN AT1 ANTAGONISTS FOR HYPERTENSION (Larry Yet).

9.1 Introduction.

9.2 Losartan Potassium.

9.2.1 Introduction to Losartan Potassium.

9.2.2 Synthesis of Losartan Potassium.

9.3 Valsartan.

9.3.1 Introduction to Valsartan.

9.3.2 Synthesis of Valsartan.

9.4 Irbesartan.

9.4.1 Introduction to Irbesartan.

9.4.2 Synthesis of Irbesartan.

9.5 Candesartan Cilexetil.

9.5.1 Introduction to Candesartan Cilexetil.

9.5.2 Synthesis of Candesartan Cilexetil.

9.6 Olmesartan Medoxomil.

9.6.1 Introduction to Olmesartan Medoxomil.

9.6.2 Synthesis of Olmesartan Medoxomil.

9.7 Eprosartan Mesylate.

9.7.1 Introduction to Eprosartan Mesylate.

9.7.2 Synthesis of Eprosartan Mesylate.

9.8 Telmisartan.

9.8.1 Introduction to Telmisartan.

9.8.2 Synthesis of Telmisartan.

References.

10 LEADING ACE INHIBITORS FOR HYPERTENSION (Victor J. Cee and Edward J. Olhava).

10.1 Introduction.

10.2 Synthesis of Enalapril Maleate.

10.3 Synthesis of Lisinopril.

10.4 Synthesis of Quinapril.

10.5 Synthesis of Benazepril.

10.6 Synthesis of Ramipril.

10.7 Synthesis of Fosinopril Sodium.

References.

11 DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS FOR HYPERTENSION (Daniel P. Christen).

11.1 Introduction.

11.2 Synthesis of Nifedipine (Adalatw).

11.3 Synthesis of Felodepine (Plendilw).

11.4 Synthesis of Amlodipine Besylate (Norvascw).

11.5 Synthesis of Azelnidipine (Calblockw).

References.

12 SECOND-GENERATION HMG-CoA REDUCTASE INHIBITORS (Jeffrey A. Pfefferkorn).

12.1 Introduction.

12.2 Synthesis of Fluvastatin (Lescolw).

12.3 Synthesis of Rosuvastatin (Crestorw).

12.4 Synthesis of Pitavastatin (Livalow).

References.

13 CHOLESTEROL ABSORPTION INHIBITORS: EZETIMIBE (ZETIA) (Stuart B. Rosenblum).

13.1 Introduction.

13.2 Discovery Path to Ezetimibe.

13.3 Synthesis of Ezetimibe (Zetia).

References.

III CENTRAL NERVOUS SYSTEM DISEASES.

14 DUAL SELECTIVE SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SSNRIs) FOR DEPRESSION (Marta Piñeiro-Núñez)

14.1 Introduction.

14.2 Synthesis of Venlafaxine.

14.3 Synthesis of Milnacipran.

14.4 Synthesis of Duloxetine.

References.

15 GABAA RECEPTOR AGONISTS FOR INSOMNIA: ZOLPIDEM (AMBIEN), ZALEPLON (SONATA), ESZOPICLONE (ESTORRA, LUNESTA), AND INDIPLON (Peter R. Guzzo).

15.1 Introduction.

15.2 Synthesis of Zolpidem.

15.3 Synthesis of Zaleplon.

15.4 Synthesis of Eszopiclone.

15.5 Synthesis of Indiplon.

References.

16 a2d LIGANDS: NEURONTIN (GABAPENTIN) AND LYRICA (PREGABALIN) (Po-Wai Yuen).

16.1 Introduction.

16.2 Synthesis of Gabapentin.

16.3 Synthesis of Pregabalin.

References.

17 APPROVED TREATMENTS FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER: AMPHETAMINE (ADDERALL), METHYLPHENIDATE (RITALIN), AND ATOMOXETINE (STRATERRA) (David L. Gray).

17.1 Introduction.

17.1.1 Stimulant versus Nonstimulants.

17.2 Synthesis of Amphetamine.

17.2.1 Pharmacokinetic Properties of d- and l-Amphetamine.

17.2.2 Chiral Synthesis of Amphetamine.

17.3 Synthesis of Methylphenidate.

17.3.1 Methylphenidate Formulations.

17.3.2 Chiral Synthesis of Methylphenidate.

17.4 Synthesis of Atomoxetine.

References.

Index.

Read More Show Less

Customer Reviews

Be the first to write a review
( 0 )
Rating Distribution

5 Star

(0)

4 Star

(0)

3 Star

(0)

2 Star

(0)

1 Star

(0)

Your Rating:

Your Name: Create a Pen Name or

Barnes & Noble.com Review Rules

Our reader reviews allow you to share your comments on titles you liked, or didn't, with others. By submitting an online review, you are representing to Barnes & Noble.com that all information contained in your review is original and accurate in all respects, and that the submission of such content by you and the posting of such content by Barnes & Noble.com does not and will not violate the rights of any third party. Please follow the rules below to help ensure that your review can be posted.

Reviews by Our Customers Under the Age of 13

We highly value and respect everyone's opinion concerning the titles we offer. However, we cannot allow persons under the age of 13 to have accounts at BN.com or to post customer reviews. Please see our Terms of Use for more details.

What to exclude from your review:

Please do not write about reviews, commentary, or information posted on the product page. If you see any errors in the information on the product page, please send us an email.

Reviews should not contain any of the following:

  • - HTML tags, profanity, obscenities, vulgarities, or comments that defame anyone
  • - Time-sensitive information such as tour dates, signings, lectures, etc.
  • - Single-word reviews. Other people will read your review to discover why you liked or didn't like the title. Be descriptive.
  • - Comments focusing on the author or that may ruin the ending for others
  • - Phone numbers, addresses, URLs
  • - Pricing and availability information or alternative ordering information
  • - Advertisements or commercial solicitation

Reminder:

  • - By submitting a review, you grant to Barnes & Noble.com and its sublicensees the royalty-free, perpetual, irrevocable right and license to use the review in accordance with the Barnes & Noble.com Terms of Use.
  • - Barnes & Noble.com reserves the right not to post any review -- particularly those that do not follow the terms and conditions of these Rules. Barnes & Noble.com also reserves the right to remove any review at any time without notice.
  • - See Terms of Use for other conditions and disclaimers.
Search for Products You'd Like to Recommend

Recommend other products that relate to your review. Just search for them below and share!

Create a Pen Name

Your Pen Name is your unique identity on BN.com. It will appear on the reviews you write and other website activities. Your Pen Name cannot be edited, changed or deleted once submitted.

 
Your Pen Name can be any combination of alphanumeric characters (plus - and _), and must be at least two characters long.

Continue Anonymously

    If you find inappropriate content, please report it to Barnes & Noble
    Why is this product inappropriate?
    Comments (optional)